Theodore Coutilish, Author at Fragile X Research - FRAXA Research Foundation • Page 2 of 2

Double Down: Fragile X Clinical Trial Combines Two Available Drugs

Theodore Coutilish Clinical • Clinical Trials • Corbin, Francois • Research Updates • University of Sherbrooke, Canada May 16, 2016June 14, 2018autism, lovastatin, minocycline, MRI

Jean-Francois Lepage, PhD, and Francois Corbin, MD, PhD, with MRI machine If all the science world’s a stage, Fragile X researchers are more than merely players. They are center stage. So believes Francois Corbin, MD, PhD, professor, Université de Sherbrooke, Canada, who directs the university’s Fragile X Clinic. Corbin, who has received more than $100,000 in FRAXA support since 2012, is leading a pilot randomized Phase II trial, exploring the tolerability and the synergistic effect of a combined therapy. They will combine minocycline, which is often used to treat acne, and lovastatin, which is used to lower cholesterol. Both drugs target specific alterations in the brain of Fragile X patients that would potentially have a combined powerful effect on their behavior. “To my knowledge, this is the first time we have a clinical trial with two different drugs combined to act on two different targets,” Corbin said. “The combined actionRead more

The X Factor – Turning on X Chromosome Genes to Treat X-linked Disorders

Theodore Coutilish Genetic Rescue • Harvard University • Lee, Jeannie • Research Updates May 9, 2016July 26, 2018epigenetics, Rett syndrome

Harvard researcher Jeannie T. Lee, MD, PhD, moves closer to turning on select genes on the X chromosome to treat people with X-linked disorders

Can STEP Inhibitors Treat Fragile X Syndrome? Yale Professor Investigates

Theodore Coutilish Research Updates March 28, 2016July 23, 2018Alzheimer's, STEP (STriatal-Enriched protein tyrosine Phosphatase)

Yale Professor Paul Lombroso, MD, looks to improve cognitive and social behaviors in those affected by Fragile X thanks to FRAXA support It’s been 25 years since Paul Lombroso, MD, first discovered the STEP protein (STriatal-Enriched protein tyrosine Phosphatase). In its simplest terms, STEP is a protein found only in the brain; is critical as people learn and develop social behavior; impacts how short memory becomes long-term memory; and regulates synapsis strengthening and intracellular signaling. When STEP elevates, as occurs in those with Fragile X syndrome and many other disorders, it significantly impacts cognitive and memory development and social behaviors. “My first decade of research was to understand STEP,” said Lombroso, the Elizabeth Mears and House Jameson Professor in the Child Study Center and the Director of Laboratory of Molecular Neurobiology, Yale University. “What was it doing in the brain …. what was it regulating?” Now Lombroso is engaged inRead more